By Colin Kellaher


Roche Holding AG on Tuesday said the U.S. Food and Drug Administration granted emergency-use authorization for its Elecsys anti-SARS-CoV-2 S antibody test.

The Swiss pharmaceutical company said the semi-quantitative blood test can be used to measure the level of antibodies in people who have been exposed to the SARS-CoV-2 virus.

Roche said the test specifically detects antibodies against the SARS-CoV-2 spike protein, which is the target of many Covid-19 vaccines in development.

Roche said it will begin shipping the Elecsys test in the next week, adding that Laboratory Corp. of America will be the first lab to offer the testing option in the U.S.


Write to Colin Kellaher at


(END) Dow Jones Newswires

December 01, 2020 11:58 ET (16:58 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.